Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 615Unknown 155Terminated 153Recruiting 143Not yet recruiting 64Active not recruiting 51Withdrawn 37Suspended 3Enrolling by invitation 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Carcinoma, Hepatocellular 1Advanced Breast Cancer 1

Interventions

Cisplatin 4130-nm albumin-bound paclitaxel 3camrelizumab 2Oxaliplatin 2Nivolumab 2Magnetic Resonance Spectroscopy 2Laparoscopy 2Bevacizumab 2trilaciclib 1trastuzumab deruxtecan 1toripalimab 1selinexor 1sacituzumab govitecan 1ribociclib 1olaparib 1nimotuzumab 1lenvatinib 1fluorodopa F 18 1durvalumab 1decitabine and cedazuridine drug combination 1dalpiciclib 1cemiplimab 1carfilzomib 1apatinib 1anlotinib 1abemaciclib 1Valacyclovir 1Temozolomide 1Taxes 1Surgical Procedures, Operative 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Enrolling by invitation × Bevacizumab × Clear all
NCT05441475 2026-02-25

A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab or SOC in HCC Patients

Abbisko Therapeutics Co, Ltd

Phase 2 Enrolling by invitation
118 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT07359404 2026-01-22

Sacituzumab Govitecan Plus Bevacizumab in Metastatic TNBC

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Enrolling by invitation
60 enrolled
Breast

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡